1. Insulet touts glucose control study
Insulet Corp. announced the results from its first feasibility study of its Omnipod Horizon hybrid closed-loop system in a Feb. 17 news release. The positive results showed that the glucose control algorithm performed well and was safe to used day and night for adults who have type 1 diabetes. It also showed that it was effective at night with minimal hypoglycemia and fasting glucose. The Insulet study had 24 participants with type 1 diabetes and took place over a 36 hour period. The participants used a modified version of the Omnipod, a Dexcom continuous glucose sensor, and a model predictive control algorithm created by Insulet.
2. Pixium announces first Spanish implantation of Iris II ‘bionic eye’
The Institute of Ocular Microsurgery in Barcelona, Spain implanted the bionic vision system Iris II in the first Spanish patient, according to a Feb. 16 news release. The vision system has a bio-inspired camera and a 150-electrode epiretinal implant that can be removed if needed. Pixium Vision developed the bionic vision system to help patients who have lost their eyesight, and the Iris II is designed to help patients who lost their eyesight from retinitis pigmentosa. The surgery was performed by Dr. Borja Corcostegui, founder and medical director of the Institute of Ocular Microsurgery and a vitreoretinal surgeon.
3. Valeritas releases data for V-Go wearable insulin delivery device
Valeritas Holdings recently touted in a Feb. 16 news release that its V-Go Wearable Insulin Delivery device proved to have a greater reduction in A1c and insulin dose in patients who have type 2 diabetes. The study analyzed the electronic medical records from a multicenter diabetes system in the U.S. It evaluated the data of 107 patients to determine that patients had fewer insulin doses and needle sticks while using the V-Go, compared to using insulin pens.